LinkMed

The LinkMed portfolio consists of a number of life science companies, several of which are nearing the commercialization phase, while others are already selling their products or services. Between them, these companies account for more than 50 different projects in a wide range of therapeutic areas – from HIV and cancer to eye disease and allergies.

COMPANIES IN SEVERAL SECTORS
LinkMed has created a portfolio of twelve companies, four in drug development and biotechnology and eight in diagnostics and medical technology

MANY COMPANIES, LOWER RISKS
By investing in several companies, we spread risks and reduce our exposure to the development in individual projects. Our goal is to continually develop and manage between 15 and 20 portfolio companies. Therefore, we plan to invest in several new companies in the coming years.

Monoclonal antibodies for apoptosis

Operations: IMED develops human monoclonal antibodies (MAB) that block or induce natural cell death or apoptosis. The company intends to develop antibodies for major therapeutic areas, including HIV, cancer and transplantation.

Sektor: Drug development and biotechnology

Therapeutic area: Cancer, HIV, transplantation

CEO: Dr. Magnus Doverskog

Chairman: Carl-Gustaf Johnsson

Venture manager: Ingemar Lagerlöf

Ownership stake: 42.2 %

Address: IMED AB
Nobelsväg 3
SE-171 77 Stockholm

Back